Evaluating the health economic impact of cefepime/enmetazobactam in complicated urinary tract infections in the German setting: a cost analysis from payer perspective
The analysis shows that a higher probability of relapse after antibiotic therapy might be associated with an increase in treatment costs within the German healthcare system. Although per-patient cost differences between cefepime/enmetazobactam and piperacillin/tazobactam are moderate, their cumulative impact at the population level could be substantial, emphasizing the broader health-economic relevance of treatment choice for cUTI.
Authors
- Florian Kron (ORCID: https://orcid.org/0000-0003-4907-7490)
- J. D. Roder (ORCID: https://orcid.org/0009-0009-7098-6753)
- Jörg Janne Vehreschild (ORCID: https://orcid.org/0000-0002-5446-7170)
- Sebastian Wingen‐Heimann (ORCID: https://orcid.org/0000-0002-4232-6944)
- Danila Seidel
- Oliver Witzke
- Melina S. Kurte
- Ann-Cathrine Froitzheim
- Oliver A. Cornely
Institutions
- Goethe University Frankfurt (DE)
- University of Cologne (DE)
- FOM University of Applied Sciences for Economics and Management (DE)
- Düsseldorf University Hospital (DE)
- Integrated Oncology (United States) (US)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- German Center for Infection Research (DE)
- QUIRIS Healthcare (DE)
- University Hospital Frankfurt (DE)
- Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE)
- University Hospital Cologne (DE)
- Heinrich Heine University Düsseldorf (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Infection
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1007/s15010-025-02711-9
- Primary Topic
- Urinary Tract Infections Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00